Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

September 16th 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Research Team in Canada Explores PARP's Complex Role in DNA Repair

September 9th 2013

Recently, Girish M. Shah's team has been using cellular and murine models to examine various therapeutic options, including inhibitor and gene knockout approaches against the DNA damage-responsive enzyme poly(ADP-ribose) polymerase 1 (PARP-1).

Dr. Garcia on the Future Role of PARP inhibitors

September 9th 2013

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Maintenance Olaparib Resurrected for Phase III Program

September 4th 2013

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

CA-125 Monitoring Shows Benefit in Early Detection of Ovarian Cancer

August 26th 2013

A two-pronged approach that includes carbohydrate antigen 125 (CA-125) testing proved highly accurate in screening women for ovarian cancer, including aggressive forms of the disease.

Ovarian Cancer Chemoresponse Assay Demonstrates Utility

August 20th 2013

The use of a chemoresponse assay to assess therapy choices for patients with recurrent ovarian cancer correlated with dramatic improvements in overall survival and progression-free survival.

Nearly Two-Thirds of Ovarian Cancer Patients Not Receiving NCCN-Recommended Treatment

July 18th 2013

An analysis of more than 13,000 patients with ovarian cancer found that only around 37% of patients receive care that adheres to the NCCN guidelines.

IP Chemo Improves Long-Term Survival in Ovarian Cancer

July 15th 2013

Women with advanced ovarian cancer lived almost a year longer when treated with intraperitoneal chemotherapy instead of intravenous therapy.

Research Spotlight: Promising Phase I Results

July 12th 2013

Highlights of key findings from several phase I clinical trials that provide insight into new and emerging druggable targets and targeted therapies.

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study

July 9th 2013

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.

Dr. Aghajanian on PARP Inhibitors for Ovarian Cancer

July 3rd 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the treatment of ovarian cancer with PARP inhibitors.

PARP Inhibitor Active in Recurrent BRCA-Mutant Ovarian Cancer

June 28th 2013

A dual-action PARP inhibitor has shown sufficient clinical activity to continue its investigation in women with recurrent BRCA-mutant ovarian cancer.

Ellen Matloff on the Supreme Court Gene Patenting Decision

June 25th 2013

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

June 25th 2013

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

Dr. Robertson on Olaparib for Serous Ovarian Cancer

June 24th 2013

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Beyond Guidelines: Conventional Wisdom About Strict Adherence Can Be Misleading

June 18th 2013

Clinical judgment may appropriately decide that based on a particular patient's medical status it may not be in that individual's best interest to undergo guideline-based therapy.

Trebananib Significantly Improves PFS in Ovarian Cancer

June 12th 2013

Treatment with the investigational agent trebananib resulted in a significant reduction in the risk of progression or death in patients with recurrent ovarian cancer, according to a phase III study.

Vinegar Proves to Be Effective, Widely Implementable Cervical Cancer Screening Tool

June 4th 2013

A simple visual screening test using vinegar has the potential to dramatically reduce the number of deaths from cervical cancer in the developing world, according to findings from a large study in India, where use of the screening tool yielded a 31% reduction in cervical cancer mortality.

Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer

June 2nd 2013

An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

June 1st 2013

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.